EDNRB and neoplasm: More relevant, it has been demonstrated that ET-1R blockade by using macitentan, a dual ETAR/ETBR receptor antagonist, beside to interfere with ETAR-driven tumor growth and progression, is able to impair ETBR-mediated vascularization of ovarian cancer xenografts.